Sight Sciences Announces Significant Head-to-Head Study on MIGS Technologies for Glaucoma Patients

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company, has unveiled the results of a comprehensive real-world clinical outcomes study evaluating the efficacy of three leading minimally invasive glaucoma surgery (MIGS) technologies in combination with cataract surgery, compared to cataract surgery alone, in over 100,000 glaucoma patient eyes. The study findings were presented at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria.

Using the American Academy of Ophthalmology’s IRIS® Registry, the largest clinical data registry in medicine and the first comprehensive eye disease clinical registry in the United States, the study assessed long-term 2-year post-surgical outcomes for patients treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices (OMNI Surgical System, Hydrus® Microstent marketed by Alcon, and iStent inject® marketed by Glaukos) combined with cataract surgery, and for patients who underwent cataract surgery alone.

The study included 77,391 glaucoma patients and 109,745 glaucomatous eyes. 6,632 patients and 9,000 eyes received a MIGS procedure combined with cataract surgery, while the remainder received cataract surgery alone. The baseline population was homogeneous, with similar mean intraocular pressure (IOP) and the number of IOP-lowering medications across cohorts. At 24 months, high baseline IOP (>18 mmHg) patients who received the TCOR procedure using OMNI technology showed the greatest numerical reduction in IOP  which was the primary analysis. Patients using the OMNI Surgical system had a mean reduction in IOP of 6.64 mmHg. Low baseline IOP (≤18 mmHg) patients who received the TCOR procedure using OMNI technology demonstrated the greatest mean medication reduction compared to all other treatment groups at 24 months with mean medication reduction of 1.42.

Trabeculocanalicular Outflow Restoration (TCOR), powered by OMNI Surgical System technology offers an implant-free, ab interno procedure addressing the three primary points of outflow resistance. It has received FDA clearance for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

Dr. Andrew Tatham, consultant ophthalmic surgeon at Princess Alexandra Eye Pavilion, Edinburgh, emphasized the value of TCOR in providing sustained IOP control, addressing the needs of patients with glaucoma, which requires around-the-clock management.

Glaucoma is a major global cause of irreversible blindness, affecting millions of people, with an estimated three million Americans affected and annual healthcare costs of $2.9 billion. Initial treatment options include eye drops or laser therapy to lower intraocular pressure. Surgical procedures like trabeculectomy are reserved for severe cases due to their risks and recovery times. Micro Invasive Glaucoma Surgery (MIGS), introduced in the early 2000s, addresse these issues and bridges the treatment gap. MIGS is suitable for mild to moderate glaucoma, drop-intolerant or noncompliant patients, and those with uncontrolled pressure despite other treatments. It offers a high safety profile, minimal disruption of eye anatomy, an ab interno approach, meaningful pressure reduction, and ease of use for both patients and physicians. However, for advanced cases requiring very low intraocular pressure, traditional surgeries may still be necessary.